Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALGS 
Aligos Therapeutics Inc (ALGS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ALGS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $90.33
1 Year Target Price $90.33
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.44% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.75M USD | Price to earnings Ratio - | 1Y Target Price 90.33 |
Price to earnings Ratio - | 1Y Target Price 90.33 | ||
Volume (30-day avg) 3 | Beta 2.69 | 52 Weeks Range 3.76 - 46.80 | Updated Date 07/12/2025 |
52 Weeks Range 3.76 - 46.80 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6187.46% |
Management Effectiveness
Return on Assets (TTM) -38.74% | Return on Equity (TTM) -60.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -78867264 | Price to Sales(TTM) 16.44 |
Enterprise Value -78867264 | Price to Sales(TTM) 16.44 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 5314800 | Shares Floating 2941280 |
Shares Outstanding 5314800 | Shares Floating 2941280 | ||
Percent Insiders 10.44 | Percent Institutions 65.64 |
Upturn AI SWOT
Aligos Therapeutics Inc
Company Overview
History and Background
Aligos Therapeutics, Inc. was founded in 2018 and is focused on developing novel therapeutics to address liver diseases. They've progressed through various preclinical and clinical stages, with a focus on chronic hepatitis B virus (CHB) and nonalcoholic steatohepatitis (NASH).
Core Business Areas
- Chronic Hepatitis B (CHB): Development of multiple therapeutic modalities aimed at achieving functional cure for CHB.
- Nonalcoholic Steatohepatitis (NASH): Development of therapies targeting key pathways involved in NASH pathogenesis.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure involves research, development, clinical, and commercial operations.
Top Products and Market Share
Key Offerings
- ALG-010133: An antisense oligonucleotide designed to reduce HBsAg, a key viral protein in CHB. Currently in clinical trials. Limited market share at this stage (pre-revenue). Competitors: Roche (RG6346), GSK (bepirovirsen).
- Other CHB programs: Aligos has several other pre-clinical programs targeting different aspects of the HBV lifecycle. Market share is currently zero, as these are pre-clinical. Competitors: Gilead, Assembly Biosciences.
- NASH programs: Aligos had a NASH program targeting thyroid hormone receptor beta but has since shifted focus to CHB. No current market share. Prior competitors included: Madrigal Pharmaceuticals, Viking Therapeutics.
Market Dynamics
Industry Overview
The liver disease therapeutics market is experiencing significant growth, driven by increasing prevalence of CHB and NASH. High unmet medical need and growing awareness are fueling research and development efforts.
Positioning
Aligos is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for liver diseases. They are competing with larger pharmaceutical companies and smaller biotech firms.
Total Addressable Market (TAM)
The CHB market is estimated to be worth billions of dollars annually. NASH's TAM is also significant and growing. Aligos is positioned to capture a portion of these markets with successful products.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in liver disease
- Diverse pipeline of therapeutic candidates
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Clinical trial risks and uncertainties
- Dependence on successful development of lead programs
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancements in liver disease research and diagnostics
- Expansion into new therapeutic areas within liver disease
Threats
- Competition from established players
- Regulatory hurdles and delays
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- GILD
- VIR
- ROCHE
- GSK
- ABUS
Competitive Landscape
Aligos faces intense competition from larger pharmaceutical companies with established market presence. Their competitive advantage lies in their differentiated therapeutic approaches and strong scientific expertise.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and clinical trial progress.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for ALG-010133 and exploring partnerships for other programs.
Summary
Aligos Therapeutics is a clinical-stage biotech company with a focus on liver diseases. They possess strong scientific expertise and a diverse pipeline, but face significant clinical and financial risks. Positive clinical trial results are crucial for future success. They need to be aware of larger competitors and possible cashflow issues.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is an estimation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aligos Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-10-16 | CEO, President & Chairman of the Board Dr. Lawrence M. Blatt MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.aligos.com |
Full time employees 70 | Website https://www.aligos.com | ||
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.